Feasibility and Preliminary Effectiveness of Varenicline for Treating Co-Occurring Cannabis and Tobacco Use

Journal of Psychoactive Drugs

Volumn 50, Issue 1, 2018, Pages 12-18

  Adams, Tangeria R ^a,b   Arnsten, Julia H ^a   Ning, Yuming ^a   Nahvi, Shadi ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Cannabis; concurrent use; feasibility; tobacco; varenicline

Indexed keywords

BUPRENORPHINE; CANNABIS; VARENICLINE;

ADULT; ARTICLE; CANNABIS USE; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PILOT STUDY; QUESTIONNAIRE; TOBACCO USE; TREATMENT OUTCOME; ADMINISTRATION AND DOSAGE; ADVERSE EVENT; BEHAVIOR THERAPY; CANNABIS ADDICTION; COMPARATIVE STUDY; CONTROLLED STUDY; CRAVING; CROSSOVER PROCEDURE; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TOBACCO DEPENDENCE;

ADULT; BEHAVIOR THERAPY; CRAVING; CROSS-OVER STUDIES; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; PILOT PROJECTS; SMOKING CESSATION AGENTS; TOBACCO USE DISORDER; VARENICLINE;

EID: 85030175174     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2017.1370746     Document Type: Article

References (38)

1. Agrawal, A., and M., Lynskey. 2009. Tobacco and cannabis co-occurrence: Does route of administration matter? Drug and Alcohol Dependence 99:240–47. doi:10.1016/j.drugalcdep.2008.08.007.
2. Agrawal, A., P., Madden, K., Bucholz, A., Heath, and M., Lynskey. 2008. Transitions to regular smoking and to nicotine dependence in women using cannabis. Drug and Alcohol Dependence 95:107–14. doi:10.1016/j.drugalcdep.2007.12.017.
3. Anthenelli, R. M., N. L., Benowitz, R., West, L., St Aubin, T., McRae, D., Lawrence, J., Ascher, C., Russ, A., Krishen, and A. E., Evins. 2016. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): A double-blind, randomised, placebo-controlled clinical trial. Lancet 387 (10037):2507–20. doi:10.1016/S0140-6736(16)30272-0.
4. Becker, J., S., Haug, T., Kraemer, and M. P., Schaub. 2015. Feasibility of a group cessation program for co-smokers of cannabis and tobacco. Drug and Alcohol Review 34 (4):418–26. doi:10.1111/dar.12244.
5. Belanger, R., C., Akre, E., Kuntsche, G., Gmel, and J.-C., Suris. 2011. Adding tobacco to cannabis: Its frequency and likely implications. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco 13:746–50. doi:10.1093/ntr/ntr043.
6. Budney, A., R., Roffman, R., Stephens, and D., Walker. 2007. Marijuana dependence and its treatment. Addiction Science & Clinical Practice 4:4–16. doi:10.1151/ASCP07414.
7. Budney, A. J., P. L., Novy, and J. R., Hughes. 1999. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 94 (9):1311–22. doi:10.1046/j.1360-0443.1999.94913114.x.
8. Center for Behavioral Health Statistics and Quality. 2015. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health (HHS Publication No. SMA 15-4927, NSDUH Series H-50). http://www.samhsa.gov/data/
9. De Dios, M. A., B. J., Anderson, C. M., Caviness, and M. D., Stein. 2014. Early quit days among methadone-maintained smokers in a smoking cessation trial. Nicotine & Tobacco Research 16 (11):1463–69. doi:10.1093/ntr/ntu099.
10. De Dios, M. A., E. L., Vaughan, C. A., Stanton, and R., Niaura. 2009. Adolescent tobacco use and substance abuse treatment outcomes. Journal of Substance Abuse Treatment 37 (1):17–24. doi:10.1016/j.jsat.2008.09.006.
11. Gonzales, D., S. I., Rennard, M., Nides, C., Oncken, S., Azoulay, C. B., Billing, E. J., Watsky, J., Gong, K. E., Williams, and K. R., Reeves, for the Varenicline Phase 3 Study Group. (2006). Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296 (1):47–55. doi: 10.1001/jama.296.1.47.
12. Haney, M., G., Bedi, Z. D., Cooper, A., Glass, S. K., Vosburg, S. D., Comer, and R. W., Foltin. 2013. Predictors of marijuana relapse in the human laboratory: Robust impact of tobacco cigarette smoking status. Biological Psychiatry 73 (3):242–48. doi:10.1016/j.biopsych.2012.07.028.
13. Heishman, S. J., E. G., Singleton, and A., Liguori. 2001. Marijuana craving questionnaire: Development and initial validation of a self-report instrument. Addiction 96 (7):1023–34. doi:10.1046/j.1360-0443.2001.967102312.x.
14. Hill, K. P., L. H., Toto, S. E., Lukas, R. D., Weiss, G. H., Trksak, J. M., Rodolico, and S. F., Greenfield. 2013. Cognitive behavioral therapy and the nicotine transdermal patch for dual nicotine and cannabis dependence: A pilot study. The American Journal on Addictions 22 (3):233–38. doi:10.1111/j.1521-0391.2012.12007.x.
15. Jorenby, D., J. T., Hays, N. A., Rigotti, S., Azoulay, E. J., Watsky, K. E., Williams, C. B., Billing, J., Gong, and K. R., Reeves, for the Varenicline Phase 3 Study Group. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 296 (1):56–63. doi: 10.1001/jama.296.1.56.
16. Lee, D. C., A. J., Budney, M. F., Brunette, J. R., Hughes, J. F., Etter, and C., Stanger. 2014. Treatment models for targeting tobacco use during treatment for cannabis use disorder: Case series. Addictive Behaviors 39 (8):1224–30. doi:10.1016/j.addbeh.2014.04.010.
17. Marshall, K., L., Gowing, R., Ali, and B., Le Foll. 2014. Pharmacotherapies for cannabis dependence. Cochrane Database of Systematic Reviews (Online) 12:CD008940.
18. Mihalak, K. B., F. I., Carroll, and C. W., Luetje. 2006. Varenicline is a partial agonist at α4β2 and a full agonist at α7 neuronal nicotinic receptors. Molecular Pharmacology 70 (3):801–05. doi:10.1124/mol.106.025130.
19. Mitchell, J. M., C. H., Teague, A. S., Kayser, S. E., Bartlett, and H. L., Fields. 2012. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology 223 (3):299–306. doi:10.1007/s00213-012-2717-x.
20. Moitra, E., B. J., Anderson, and M. D., Stein. 2013. Perceived stress and substance use in methadone-maintained smokers. Drug and Alcohol Dependence 133 (2):785–88. doi:10.1016/j.drugalcdep.2013.08.010.
21. Moore, B., and A., Budney. 2001. Tobacco smoking in marijuana-dependent outpatients. Journal of Substance Abuse 13:583–96. doi:10.1016/S0899-3289(01)00093-1.
22. Nahvi, S., Y., Ning, K. S., Segal, K. P., Richter, and J. H., Arnsten. 2014. Varenicline efficacy and safety among methadone maintained smokers: A randomized placebo-controlled trial. Addiction 109 (9):1554–63. doi:10.1111/add.2014.109.issue-9.
23. Newcombe, D. A., N., Walker, J., Sheridan, and S., Galea. 2015. The effect of varenicline administration on cannabis and tobacco use in cannabis and nicotine dependent individuals: A case series. Journal of Addiction Research & Therapy 6 (2):1–5. doi:10.4172/2155-6105.1000222.
24. Patton, G., C., Coffey, J., Carlin, S., Sawyer, and M., Lynskey. 2005. Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 100:1518–25. doi:10.1111/add.2005.100.issue-10.
25. Penetar, D. M., E. M., Kouri, M. M., Gross, E. M., McCarthy, C. K., Rhee, E. N., Peters, and S. E., Lukas. 2005. Transdermal nicotine alters some of marihuana’s effects in male and female volunteers. Drug and Alcohol Dependence 79 (2):211–23. doi:10.1016/j.drugalcdep.2005.01.008.
26. Plebani, J. G., 2012. Results of an initial clinical trial of varenicline for the treatment of cocaine dependence. Drug and Alcohol Dependence 121 (1–2):163–66. doi:10.1016/j.drugalcdep.2011.08.025.
27. Plebani, J. G., K. G., Lynch, L., Rennert, H. M., Pettinati, C. P., O’Brien, and K. M., Kampman. 2013. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug and Alcohol Dependence 133 (2):754–58. doi:10.1016/j.drugalcdep.2013.06.019.
28. Posner, K., M. A., Oquendo, M., Gould, B., Stanley, and M., Davies. 2007. Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. The American Journal of Psychiatry 164 (7):1035–43. doi:10.1176/ajp.2007.164.7.1035.
29. Rabin, R. A., and T. P., George. 2015. A review of co-morbid tobacco and cannabis use disorders: Possible mechanisms to explain high rates of co-use. The American Journal on Addictions/American Academy of Psychiatrists in Alcoholism and Addictions 24 (2):105–16. doi:10.1111/ajad.v24.2.
30. Ramo, D., and J., Prochaska. 2012. Prevalence and co-use of marijuana among young adult cigarette smokers: An anonymous online national survey. Addiction Science & Clinical Practice 7 (1):5. doi:10.1186/1940-0640-7-5.
31. Richter, K. P., C. A., Gibson, J. S., Ahluwalia, and K. H., Schmelzle. 2001. Tobacco use and quit attempts among methadone maintenance clients. American Journal of Public Health 91 (2):296–99. doi:10.2105/AJPH.91.2.296.
32. Rohsenow, D. J., J. W., Tidey, R. A., Martin, S. M., Colby, R. M., Swift, L., Leggio, and P. M., Monti. 2017. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: Effects on smoking, substance use and depressive symptoms. Addiction 112 (10):1808–1820. doi: 10.1111/add.13861.
33. Schauer, G. L., C. J., Berg, M. C., Kegler, D. M., Donovan, and M., Windle. 2016. Differences in tobacco product use among past month adult marijuana users and nonusers: Findings from the 2003–2012 national survey on drug use and health. Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco 18 (3):281–88. doi:10.1093/ntr/ntv093.
34. Sheehan, D. V., Y., Lecrubier, K. H., Sheehan, P., Amorim, J., Janavs, E., Weiller, T., Hergueta, R., Baker, and G. C., Dunbar. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry 59 (Suppl 20):22–33;quiz 34–57.
35. Solinas, M., M., Scherma, L., Fattore, J., Stroik, C., Wertheim, G., Tanda, W., Fratta, and S. R., Goldberg. 2007. Nicotinic alpha 7 receptors as a new target for treatment of cannabis abuse. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 27 (21):5615–20. doi:10.1523/JNEUROSCI.0027-07.2007.
36. Stein, M. D., C. M., Caviness, M. E., Kurth, D., Audet, J., Olson, and B. J., Anderson. 2013. Varenicline for smoking cessation among methadone-maintained smokers: A randomized clinical trial. Drug and Alcohol Dependence 133 (2):486–93. doi:10.1016/j.drugalcdep.2013.07.005.
37. Timberlake, D. S., B. C., Haberstick, C. J., Hopfer, J., Bricker, J. T., Sakai, J. M., Lessem, and J. K., Hewitt. 2007. Progression from marijuana use to daily smoking and nicotine dependence in a national sample of U.S. adolescents Drug and Alcohol Dependence 88 (2–3):272–81. doi:10.1016/j.drugalcdep.2006.11.005.
38. Volkow, N. D., R. D., Baler, W. M., Compton, and S. R., Weiss. 2014. Adverse health effects of marijuana use. The New England Journal of Medicine 370 (23):2219–27. doi:10.1056/NEJMra1402309.